| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Article abstract-We monitored 11 patients with advanced Parkinson's disease (PD) who entered nursing homes over a 5-year period and assessed chronicity of nursing home care, mortality, and hallucinatory status. Two years after the original study's close, none of these patients had ever been discharged from the nursing homes and all were dead. The mortality rate among the nursing home patients was significantly greater than that in 22 community-dwelling subjects with PD who were matched for age, gender, and disease duration. Hallucinatory status was generally stable; 82% of patients had the same hallucinatory status (presence or absence) at the two assessments. Four subjects from the original community-dwelling control group entered nursing homes during the follow-up period. Whereas motor and intellectual impairment scores were similar between these patients and the remaining 18 in the community, the presence of hallucinations was significantly greater among patients transferred to nursing homes. The study demonstrates the permanency of nursing home placement in advanced PD and the high mortality associated with such placement. It also documents the chronicity of hallucinatory behavior in these patients with advanced PD and reinforces our previously reported observations on the relationship between hallucinations and placement in chronic-care facilities.
NEUROLOGY 1995;45: 669-671
This article has been cited by other articles:
|
|
 |
|
  K. M. Biglan, R. G. Holloway Jr, M. P. McDermott, I. H. Richard, and The Parkinson Study Group CALM-PD Investigators Risk factors for somnolence, edema, and hallucinations in early Parkinson disease Neurology, July 10, 2007; 69(2): 187 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Aarsland, K Bronnick, U Ehrt, P P De Deyn, S Tekin, M Emre, and J L Cummings Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress J. Neurol. Neurosurg. Psychiatry, January 1, 2007; 78(1): 36 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Goetz, J. Wuu, L. M. Curgian, and S. Leurgans Hallucinations and sleep disorders in PD: Six-year prospective longitudinal study Neurology, January 11, 2005; 64(1): 81 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. T. Stebbins, C. G. Goetz, M. C. Carrillo, K. J. Bangen, D. A. Turner, G. H. Glover, and J. D.E. Gabrieli Altered cortical visual processing in PD with hallucinations: An fMRI study Neurology, October 26, 2004; 63(8): 1409 - 1416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kulisevsky and E. Roldan Hallucinations and sleep disturbances in Parkinson's disease Neurology, October 26, 2004; 63(8_suppl_3): S28 - S30. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. P. Wint, M. S. Okun, and H. H. Fernandez Psychosis in Parkinson's Disease J Geriatr Psychiatry Neurol, September 1, 2004; 17(3): 127 - 136. [Abstract] [PDF]
|
|
|
|
 |
|
 J. G. Goldman, C. G. Goetz, E. Berry-Kravis, S. Leurgans, and L. Zhou Genetic Polymorphisms in Parkinson Disease Subjects With and Without Hallucinations: An Analysis of the Cholecystokinin System Arch Neurol, August 1, 2004; 61(8): 1280 - 1284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Pollak, F Tison, O Rascol, A Destee, J J Pere, J M Senard, F Durif, and I Bourdeix Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up J. Neurol. Neurosurg. Psychiatry, May 1, 2004; 75(5): 689 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Ismail and I. H. Richard A Reality Test: How Well Do We Understand Psychosis in Parkinson's Disease? J Neuropsychiatry Clin Neurosci, February 1, 2004; 16(1): 8 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Factor, P. J. Feustel, J. H. Friedman, C. L. Comella, C. G. Goetz, R. Kurlan, M. Parsa, R. Pfeiffer, and the Parkinson Study Group Longitudinal outcome of Parkinson's disease patients with psychosis Neurology, June 10, 2003; 60(11): 1756 - 1761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V.L. Wheelock, T. Tempkin, K. Marder, M. Nance, R.H. Myers, H. Zhao, E. Kayson, C. Orme, and I. Shoulson Predictors of nursing home placement in Huntington disease Neurology, March 25, 2003; 60(6): 998 - 1001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Levy, M.-X. Tang, E.D. Louis, L.J. Cote, B. Alfaro, H. Mejia, Y. Stern, and K. Marder The association of incident dementia with mortality in PD Neurology, December 10, 2002; 59(11): 1708 - 1713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Goetz, S. Leurgans, E. J. Pappert, R. Raman, and A. B. Stemer Prospective longitudinal assessment of hallucinations in Parkinson's disease Neurology, December 11, 2001; 57(11): 2078 - 2082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Holroyd, L Currie, and G F Wooten Prospective study of hallucinations and delusions in Parkinson's disease J. Neurol. Neurosurg. Psychiatry, June 1, 2001; 70(6): 734 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Goetz, P. F. Burke, S. Leurgans, E. Berry-Kravis, L. M. Blasucci, R. Raman, and L. Zhou Genetic Variation Analysis in Parkinson Disease Patients With and Without Hallucinations: Case-Control Study Arch Neurol, February 1, 2001; 58(2): 209 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Tanner Dopamine Agonists in Early Therapy for Parkinson Disease: Promise and Problems JAMA, October 18, 2000; 284(15): 1971 - 1973. [Full Text] [PDF]
|
|
|
|
|
|
C. G. Goetz, L. M. Blasucci, S. Leurgans, and E. J. Pappert Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients Neurology, September 26, 2000; 55(6): 789 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Fenelon, F. Mahieux, R. Huon, and M. Ziegler Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors Brain, April 1, 2000; 123(4): 733 - 745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A Hely, J. G L Morris, R. Traficante, W. G J Reid, D. J O'Sullivan, and P. M Williamson The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years J. Neurol. Neurosurg. Psychiatry, September 1, 1999; 67(3): 300 - 307. [Abstract] [Full Text]
|
|
|
|
 |
|
 The Parkinson Study Group Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease N. Engl. J. Med., March 11, 1999; 340(10): 757 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Cummings Managing Psychosis in Patients with Parkinson's Disease N. Engl. J. Med., March 11, 1999; 340(10): 801 - 803. [Full Text]
|
|
|
|
|
|
I. Litvan, J. L Cummings, and M. Mega Neuropsychiatric features of corticobasal degeneration J. Neurol. Neurosurg. Psychiatry, November 1, 1998; 65(5): 717 - 721. [Abstract] [Full Text]
|
|
|
|
|
|
A. E. Lang and A. M. Lozano Parkinson's Disease- Second of Two Parts N. Engl. J. Med., October 15, 1998; 339(16): 1130 - 1143. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
